Company Overview and News

 
Chinese tech giants battle to win the Southeast Asian market

2018-09-10 channelnewsasia
SINGAPORE: Chinese tech giants Alibaba and Tencent have long been locked in a fierce battle to dominate the consumer Internet in their home country, but over the last several years, the jostle for supremacy has extended beyond China, with Southeast Asia becoming a key battleground.
0165

 
China Everbright shares crash after US$1.3b rights issue

2018-08-14 malaymail
HONG KONG, Aug 14 — China Everbright International Ltd plans to raise about HK$9.96 billion (RM5.18 billion) from a rights issue for its waste-to-energy projects, business expansion and the repayment of bank loans. The shares plunged as much as 26 per cent.
0257 CHFFF CHFFY 0165

 
OCBC's Bank of Singapore picks Luxembourg for Europe hub

2018-07-16 theedgemarkets
BENGALURU (July 16): Bank of Singapore, the private banking division of Singapore's second-largest listed lender Oversea-Chinese Banking Corp, has set up a wealth management subsidiary in Luxembourg so it can serve European customers, Luxembourg for Finance said.
O39 0165

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks - 1
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

 
A day of reckoning may be coming for China's bond market

2018-05-25 cnbc
It's a mixed bag – a green energy developer, a shoemaker, a telecom equipment manufacturer and a port on the border with North Korea.
0165

 
Is the day of reckoning coming for China’s corporate bond market?

2018-05-25 scmp
A flurry of defaults is raising expectations that there could be many more to come as Beijing clamps down on financial risk
0165

81
Ant Financial to help state lender China Everbright Bank develop fintech capabilities

2018-05-23 scmp
Ant Financial, an affiliate of Chinese e-commerce giant Alibaba Group Holding, said on Wednesday it had signed a strategic cooperation agreement with China Everbright Bank and its financial technology affiliate Everbright Technology, to help the state bank with its digital transformation.
BABA 0700 0165

81
Tencent eyes big picture as it forms partnership with Tang Media and China Everbright

2018-04-09 scmp
The Chinese internet giant’s arms – Tencent Pictures and Tencent Penguin Pictures – join hands with Tang Media and China Everbright to distribute films and produce original television content for Chinese audiences
BABA 0700 0165

16
Five Things You Need to Know to Start Your Day - Bloomberg

2018-03-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GEC GE CHJHF 55BC CHA CBQS 0165 CICHY 0728 GNE CICHF CCB 0939

 
US virtual currency trading platform Circle plans big expansion in Asia

2018-03-16 scmp
The platform, backed by IDG Capital, Goldman Sachs and Baidu, will focus on helping Asia institutions trade digital tokens
0165

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...